The economic burden of metastatic breast cancer: a U.S. managed care perspective
- 9 June 2012
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 134 (2), 815-822
- https://doi.org/10.1007/s10549-012-2097-2
Abstract
This study was performed to quantify the economic burden and identify drivers of direct costs of mBC. In a retrospective study of a de-identified administrative claims database of privately insured patients, women between 18 and 64 years of age were included if they had at least one claim with a diagnosis of breast cancer and subsequently one or more claims with a diagnosis of secondary malignancy between January 1, 2003 and December 31, 2009. The study sample was further classified into the following subgroups: (1) Endocrine therapy, (2) HER-2 targeted therapy, (3) Concomitant HER-2 targeted and endocrine therapy, (4) Cytotoxic chemotherapy, and (5) No-systemic therapy. Costs for medical resource utilization were calculated on a per patient per month (PPPM) basis. A total of 7,698 mBC patients were identified from 2003 to 2009 with an average age at index of ~52 years, and average follow up of 2.2 years. The average total direct medical costs for 7,698 mBC patients were $9,788 PPPM. Outpatient costs accounted for the majority of overall PPPM costs. Examining the five different mBC therapeutic subgroups revealed that patients who received no-systemic therapy had the highest costs at $13,926 PPPM, while patients who received systemic endocrine therapy had the lowest costs at $5,303 PPPM. This study demonstrated that mBC is associated with substantial healthcare costs in a non-Medicare patient population. Assuming average PPPM costs of $9,788 and an average life expectancy of 2.2 years, the total average expenditure to treat mBC would be ~$250,000 per patient.Keywords
This publication has 20 references indexed in Scilit:
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- Treatment of metastatic breast cancer: second line and beyondAnnals Of Oncology, 2010
- Triple-Negative Breast CancerThe Cancer Journal, 2010
- The Costs of Treating Breast Cancer in the USPharmacoEconomics, 2009
- Factors Predictive of Response to Hormone Therapy in Breast CancerTumori Journal, 2008
- Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor StatusJNCI Journal of the National Cancer Institute, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000
- Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node–Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189Journal of Clinical Oncology, 2000
- Treatment of Breast CancerNew England Journal of Medicine, 1998